Sanofi, a French multinational pharmaceutical company, agreed to acquire Kadmon, a biopharmaceutical company, for $1.9bn. "We are excited that Sanofi has acknowledged the value of Rezurock and the deep potential of our pipeline. By leveraging Sanofi’s global resources and long-standing expertise in developing and commercializing innovative medicines, Rezurock is now well positioned for global accessibility, faster. I want to thank the entire Kadmon team, including management and the Board of Directors, and the Sanofi organization, for their ongoing commitment to patients and their caregivers," Harlan Waksal, Kadmon President and CEO.